benzyl piperazine-1-carboxylate hydrochloride | 68160-42-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl piperazine-1-carboxylate hydrochloride
• 英文别名: 1-Cbz-piperazine hydrochloride；benzyl piperazine-1-carboxylate;hydrochloride
• CAS: 68160-42-9
• 化学式: C₁₂H₁₆N₂O₂*ClH
• 分子量: 256.732
• InChiKey: UVSYBACKWARTJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.65
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  41.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  benzyl piperazine-1-carboxylate hydrochloride 在 potassium cyanate 、 水 作用下， 生成 4-氨基甲酰苄基1-哌嗪羧酸酯
  参考文献：
  名称：

  Anticonvulsants. Benzyl 4-carbamyl-1-piperazinecarboxylate and related compounds

  摘要：

  DOI：

  10.1021/jo50013a007

文献信息

• [EN] METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS<br/>[FR] MÉTHODES DE RETARDEMENT, DE PRÉVENTION ET DE TRAITEMENT DE LA RÉSISTANCE ACQUISE AUX INHIBITEURS DE RAS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2021257736A1

  公开（公告）日：2021-12-23

  The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

  本公开涉及使用双-立体异构体mTOR抑制剂与RAS抑制剂联合治疗疾病或病状（例如，癌症）的配方和方法。具体而言，在某些实施方式中，本公开包括用于诱导肿瘤细胞凋亡和/或用于延迟、预防或治疗对RAS抑制剂获得性耐药性的双-立体异构体mTOR抑制剂的配方和方法。
• Use of 5-phenyl-2-furan esters, amides and ketones as neuroprotective
  申请人：Norwich Eaton Pharmaceuticals, Inc.

  公开号：US05118708A1

  公开（公告）日：1992-06-02

  The present invention encompasses methods of using a 5-phenyl-2-furan esters, amides and ketones and compositions thereof to prevent or limit neuronal death or degeneration in a human or lower animal. These methods comprise systemically administering to such human or other animal a safe and effective amount of a compound of the formula: ##STR1## wherein (1) X is halo or nil; and Y is a substituent selected from the group consisting of unsubstituted or halogen-substituted methyl, halo, nitro, amino, and methoxy; and (2) R is R.sup.1 C(O)OH, R.sup.1 C(O)N(R.sup.3).sub.2, N(R.sup.3).sub.2, OR.sup.1 N(R.sup.3).sub.2, R.sup.1 N(R.sup.3).sub.2, N(R.sup.2)R.sup.1 N(R.sup.3).sub.2, or N(R.sup.2)N(R.sup.3).sub.2 ; where R.sup.1 is C.sub.1 -C.sub.3 alkyl which is unsubstituted or substituted with C.sub.1 -C.sub.2 alkyl; R.sup.2 is hydrogen or lower alkyl; and each R.sup.3 is, independently, hydrogen or lower alkyl; or both R.sup.3 groups are connected to form a saturated 5- or 6-membered heterocycle containing 1 or 2 heteroatoms selected from oxygen and nitrogen, and said heterocycle is unsubstituted or substituted with lower alkyl or hydroxy-substituted lower alkyl; or a pharmaceutically acceptable salt thereof.

  本发明涵盖了使用5-苯基-2-呋喃酯、酰胺和酮及其组合物的方法，以预防或限制人类或较低动物中的神经细胞死亡或退化。这些方法包括向这样的人类或其他动物系统地给予化合物的安全有效量，该化合物的结构如下：其中（1）X是卤素或零；Y是选择自未取代或卤素取代的甲基、卤素、硝基、氨基和甲氧基的取代基；以及（2）R是R1C（O）OH、R1C（O）N（R3）2、N（R3）2、OR1N（R3）2、R1N（R3）2、N（R2）R1N（R3）2或N（R2）N（R3）2；其中R1是未取代或取代为C1-C3烷基的C1-C3烷基；R2是氢或较低烷基；每个R3独立地是氢或较低烷基；或者两个R3基连接形成含有1或2个来自氧和氮的杂原子的饱和的5-或6元杂环，该杂环未取代或取代为较低烷基或羟基取代的较低烷基；或其药学上可接受的盐。
• Use of 5-phenyl-2-furan esters and amides as antiepileptic agents
  申请人：Norwich Eaton Pharmaceuticals, Inc.

  公开号：US05023272A1

  公开（公告）日：1991-06-11

  A method of preventing epileptic seizures in a human or mammal subject susceptible to said seizures, comprising systemically administering to said subject a safe and effective amount of a compound of the formula: ##STR1## wherein (a) X is halo or hydrogen, and Y is a substituent selected from the group consisting of unsubstituted or halogen-substituted methyl, halo, nitro, amino, and methoxy; and (b) R is N(R.sup.3).sub.2, OR.sup.1 N(R.sup.3).sub.2, N(R.sup.2)R.sup.1 N(R.sup.3).sub.2, or N(R.sup.2)N(R.sup.3).sub.2 ; where R.sup.1 is C.sub.1 -C.sub.3 alkylene which is unsubstituted or substituted with C.sub.1 -C.sub.2 alkyl; R.sup.2 is hydrogen or lower alkyl; and each R.sup.3 is, independently, hydrogen or lower alkyl; or both R.sup.3 groups are connected to form a saturated 5- or 6-membered heterocycle containing 1 or 2 heteroatoms selected from oxygen and nitrogen and said heterocycle is unsubstituted or substituted with lower alkyl or hydroxy-substituted lower alkyl; or a pharmaceutically-acceptable salt thereof. Preferably X is halo, preferably Y is trifluoromethyl, and R is preferably 3-diethylamino-2,2-dimethylpropoxy.

  一种预防人类或哺乳动物易患癫痫发作的方法，包括向该受试者全身给予公式化合物的安全有效量：##STR1## 其中（a）X为卤素或氢，Y为从未取代或卤素取代的甲基、卤素、硝基、氨基和甲氧基中选择的取代基；和（b）R为N（R.sup.3）.sub.2、OR.sup.1 N（R.sup.3）.sub.2、N（R.sup.2）R.sup.1 N（R.sup.3）.sub.2或N（R.sup.2）N（R.sup.3）.sub.2；其中R.sup.1为未取代或取代为C.sub.1-C.sub.2烷基的C.sub.1-C.sub.3烷基；R.sup.2为氢或较低烷基；每个R.sup.3独立地为氢或较低烷基；或两个R.sup.3基团连接形成含有氧和氮中选择的1个或2个杂原子的饱和5-或6-成员杂环，该杂环未取代或取代为较低烷基或羟基取代的较低烷基；或其药学上可接受的盐。最好X为卤素，Y最好为三氟甲基，R最好为3-二乙基氨基-2,2-二甲基丙氧基。
• [EN] ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS
  申请人：BRITISH BIOTECH PHARM

  公开号：WO2004033441A1

  公开（公告）日：2004-04-22

  Compounds of formula (II) have antibacterial activity: wherein: Q represents a radical of formula -N(OH)CH(=0) or formula -C(=O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl or, except when Q is a radical of formula -N(OH)CH(=0), a hydroxy, halo or amino group; R2 represents a group R10-(D)n-(ALK)m- wherein R10 represents hydrogen or an optionally substituted C1-C6 alkyl, C2-C6 alkynyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkynylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S­linkages, D represents -NH-, -O- or -S-, and m and n are independently 0 or 1; R4 represents the side chain of a natural or non-natural alpha amino acid; ring A represents an optionally substituted monocyclic heterocyclic ring containing from 5 to 7 ring atoms, one of which is the nitrogen atom shown, the remaining ring atoms being selected from compatible combinations of carbon, oxygen, sulfur and nitrogen; X is oxygen or sulfur; Y is oxygen, sulfur or -NH-; R is 0, 1, 2 or 3; and ring B represents an optionally substituted carbocyclic or heterocyclic ring system.

  式（II）的化合物具有抗菌活性：其中：Q代表式-N（OH）CH（=0）或式-C（=O）NH（OH）的基团；R1代表氢，甲基或三氟甲基或者除非Q是式-N（OH）CH（=0）的基团，还可以是一个羟基，卤素或氨基；R2代表一个基团R10-(D)n-(ALK)m-，其中R10代表氢或者一个可选择取代的C1-C6烷基，C2-C6炔基，C2-C6炔基，环烷基，芳基或杂环烷基，ALK代表一条直链或支链的二价C1-C6烷基，C2-C6炔基或C2-C6炔基基团，并且可以被一个或多个非相邻的-NH-，-O-或-S-连接所中断，D代表-NH-，-O-或-S-，m和n独立地为0或1；R4代表天然或非天然α-氨基酸的侧链；环A代表一个可选择取代的含有5到7个环原子的单环杂环，其中之一是所示的氮原子，其余环原子选自碳，氧，硫和氮的兼容组合；X是氧或硫；Y是氧，硫或-NH-；R为0，1，2或3；环B代表一个可选择取代的碳环或杂环环系统。
• Oxygen-containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20220315598A1

  公开（公告）日：2022-10-06

  Disclosed are an oxygen-containing heterocyclic compound, a preparation method therefor and the use thereof. The present disclosure provides an oxygen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotopic compound thereof. It is expected that the oxygen-containing heterocyclic compound can treat and/or prevent various Ras-mediated diseases.

  本发明涉及一种含氧杂环化合物及其制备方法和用途。本发明提供了一种由式I表示的含氧杂环化合物，其药物可接受的盐，其立体异构体，其互变异构体或其同位素化合物。预计该含氧杂环化合物可以治疗和/或预防各种Ras介导的疾病。